Expertise in
17
conditions

Melinda J. Gooderham

Peterborough, ON, CA 
Expertise in
17
conditions
Peterborough, ON, CA 

Overview

Melinda Gooderham practices in Peterborough, Canada. Ms. Gooderham is highly rated in 17 conditions, according to our data. Her top areas of expertise are Plaque Psoriasis, Atopic Dermatitis, Psoriasis, and Pustular Psoriasis.

Her clinical research consists of co-authoring 320 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Peterborough, ON, Canada
Other Locations
Kingston, ON, Canada
Waterloo, ON, Canada
Toronto, ON, Canada
Canada
London, ON, Canada
Calgary, AB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK2982772 in Participants With Moderate to Severe Plaque Psoriasis
A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK2982772 in Participants With Moderate to Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug
Study Drug: GSK2982772
Study Phase: Phase 1
A Randomized, Double Blind and Placebo Controlled Phase 3 Study to Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
A Randomized, Double Blind and Placebo Controlled Phase 3 Study to Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Drug
Study Drug: SHR0302
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
Enrollment Status: Terminated
Publish Date: March 15, 2022
Intervention Type: Drug
Study Drugs: LY3462817-IV, LY3462817-SV
Study Phase: Phase 1
View 9 Less Clinical Trials

320 Total Publications

The Atopic Dermatitis Shared Decision-Making Tool: Implementing the AHEAD Approach in Clinical Practice.
The Atopic Dermatitis Shared Decision-Making Tool: Implementing the AHEAD Approach in Clinical Practice.
Journal: Journal of cutaneous medicine and surgery
Published: April 12, 2026

Frequently Asked Questions about Melinda J. Gooderham

Is Melinda J. Gooderham a top-rated expert for Plaque Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Melinda J. Gooderham is classified as an Elite expert for Plaque Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Melinda J. Gooderham participate in research or clinical trials?

Yes. Melinda J. Gooderham has published 320 articles and abstracts on conditions like Plaque Psoriasis. You can view a list of Melinda J. Gooderham's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gooderham's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile